Announced
Completed
Synopsis
Novomed, a company controlled by Prof. Ronald Li, CEO and a director of Novoheart, completed the acquisition of Novoheart Holdings, a global stem cell biotechnology company, for C$100m. Following closing of the transaction, Novoheart shares were de-listed from the TSXV.
Principals
Show Details & Financials
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.